Multicenter Study
. 2007 Dec 5;99(23):1782-92. doi: 10.1093/jnci/djm223. Epub 2007 Nov 27. Projecting individualized absolute invasive breast cancer risk in African American women Joseph P Costantino, David Pee, Melissa Bondy, Lisa Newman, Mano Selvan, Garnet L Anderson, Kathleen E Malone, Polly A Marchbanks, Worta McCaskill-Stevens, Sandra A Norman, Michael S Simon, Robert Spirtas, Giske Ursin, Leslie BernsteinAffiliations
AffiliationItem in Clipboard
Multicenter Study
Projecting individualized absolute invasive breast cancer risk in African American womenMitchell H Gail et al. J Natl Cancer Inst. 2007.
. 2007 Dec 5;99(23):1782-92. doi: 10.1093/jnci/djm223. Epub 2007 Nov 27. Authors Mitchell H Gail 1 , Joseph P Costantino, David Pee, Melissa Bondy, Lisa Newman, Mano Selvan, Garnet L Anderson, Kathleen E Malone, Polly A Marchbanks, Worta McCaskill-Stevens, Sandra A Norman, Michael S Simon, Robert Spirtas, Giske Ursin, Leslie Bernstein AffiliationItem in Clipboard
Erratum inBackground: The Breast Cancer Risk Assessment Tool of the National Cancer Institute (NCI) is widely used for counseling and determining eligibility for breast cancer prevention trials, although its validity for projecting risk in African American women is uncertain. We developed a model for projecting absolute risk of invasive breast cancer in African American women and compared its projections with those from the Breast Cancer Risk Assessment Tool.
Methods: Data from 1607 African American women with invasive breast cancer and 1647 African American control subjects in the Women's Contraceptive and Reproductive Experiences (CARE) Study were used to compute relative and attributable risks that were based on age at menarche, number of affected mother or sisters, and number of previous benign biopsy examinations. Absolute risks were obtained by combining this information with data on invasive breast cancer incidence in African American women from the NCI's Surveillance, Epidemiology and End Results Program and with national mortality data. Eligibility screening data from the Study of Tamoxifen and Raloxifene (STAR) trial were used to determine how the new model would affect eligibility, and independent data from the Women's Health Initiative (WHI) were used to assess how well numbers of invasive breast cancers predicted by the new model agreed with observed cancers.
Results: Tables and graphs for estimating relative risks and projecting absolute invasive breast cancer risk with confidence intervals were developed for African American women. Relative risks for family history and number of biopsies and attributable risks estimated from the CARE population were lower than those from the Breast Cancer Risk Assessment Tool, as was the discriminatory accuracy (i.e., concordance). Using eligibility screening data from the STAR trial, we estimated that 30.3% of African American women would have had 5-year invasive breast cancer risks of at least 1.66% by use of the CARE model, compared with only 14.5% by use of the Breast Cancer Risk Assessment Tool. The numbers of cancers predicted by the CARE model agreed well with observed numbers of cancers (i.e., it was well calibrated) in data from the WHI, except that it underestimated risk in African American women with breast biopsy examinations.
Conclusions: The CARE model usually gave higher risk estimates for African American women than the Breast Cancer Risk Assessment Tool and is recommended for counseling African American women regarding their risk of breast cancer.
Similar articlesMatsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH. Matsuno RK, et al. J Natl Cancer Inst. 2011 Jun 22;103(12):951-61. doi: 10.1093/jnci/djr154. Epub 2011 May 11. J Natl Cancer Inst. 2011. PMID: 21562243 Free PMC article.
Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, LaCroix AZ, Pee D, Chlebowski RT, Hines LM, Thompson CA, Gail MH. Banegas MP, et al. J Natl Cancer Inst. 2016 Dec 20;109(2):djw215. doi: 10.1093/jnci/djw215. Print 2017 Feb. J Natl Cancer Inst. 2016. PMID: 28003316 Free PMC article.
Boggs DA, Rosenberg L, Pencina MJ, Adams-Campbell LL, Palmer JR. Boggs DA, et al. J Natl Cancer Inst. 2013 Mar 6;105(5):361-7. doi: 10.1093/jnci/djt008. Epub 2013 Feb 14. J Natl Cancer Inst. 2013. PMID: 23411594 Free PMC article.
Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N. Vogel VG, et al. J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. J Natl Cancer Inst Monogr. 2010. PMID: 20956826 Free PMC article. Review.
Dunn BK, Ford LG. Dunn BK, et al. Breast J. 2001 May-Jun;7(3):144-57. doi: 10.1046/j.1524-4741.2001.007003144.x. Breast J. 2001. PMID: 11469927 Review.
Boggs DA, Rosenberg L, Adams-Campbell LL, Palmer JR. Boggs DA, et al. J Clin Oncol. 2015 Mar 20;33(9):1038-44. doi: 10.1200/JCO.2014.57.2750. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624428 Free PMC article.
Starlard-Davenport A, Allman R, Dite GS, Hopper JL, Spaeth Tuff E, Macleod S, Kadlubar S, Preston M, Henry-Tillman R. Starlard-Davenport A, et al. PLoS One. 2018 Oct 3;13(10):e0204834. doi: 10.1371/journal.pone.0204834. eCollection 2018. PLoS One. 2018. PMID: 30281645 Free PMC article.
Shvetsov YB, Wilkens LR, White KK, Chong M, Buyum A, Badowski G, Leon Guerrero RT, Novotny R. Shvetsov YB, et al. BMJ Open. 2022 Dec 9;12(12):e061205. doi: 10.1136/bmjopen-2022-061205. BMJ Open. 2022. PMID: 36600333 Free PMC article.
Zhang Z, Bien J, Mori M, Jindal S, Bergan R. Zhang Z, et al. Oncotarget. 2019 Dec 3;10(64):6898-6912. doi: 10.18632/oncotarget.27365. eCollection 2019 Dec 3. Oncotarget. 2019. PMID: 31839883 Free PMC article.
Graubard BI, Freedman AN, Gail MH. Graubard BI, et al. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2430-6. doi: 10.1158/1055-9965.EPI-10-0324. Epub 2010 Sep 14. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20841391 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3